CA2713879C - Self-assembling peptide nanoparticles useful as vaccines - Google Patents

Self-assembling peptide nanoparticles useful as vaccines Download PDF

Info

Publication number
CA2713879C
CA2713879C CA2713879A CA2713879A CA2713879C CA 2713879 C CA2713879 C CA 2713879C CA 2713879 A CA2713879 A CA 2713879A CA 2713879 A CA2713879 A CA 2713879A CA 2713879 C CA2713879 C CA 2713879C
Authority
CA
Canada
Prior art keywords
leu
arg
glu
ala
asn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2713879A
Other languages
English (en)
French (fr)
Other versions
CA2713879A1 (en
Inventor
Peter Burkhard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALPHA-O PEPTIDES AG
Original Assignee
ALPHA-O PEPTIDES AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39276265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2713879(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ALPHA-O PEPTIDES AG filed Critical ALPHA-O PEPTIDES AG
Publication of CA2713879A1 publication Critical patent/CA2713879A1/en
Application granted granted Critical
Publication of CA2713879C publication Critical patent/CA2713879C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/002Protozoa antigens
    • A61K39/015Hemosporidia antigens, e.g. Plasmodium antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/21Retroviridae, e.g. equine infectious anemia virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/64Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
CA2713879A 2008-02-01 2009-01-29 Self-assembling peptide nanoparticles useful as vaccines Active CA2713879C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08101221.3 2008-02-01
EP08101221 2008-02-01
PCT/EP2009/050996 WO2009109428A2 (en) 2008-02-01 2009-01-29 Self-assembling peptide nanoparticles useful as vaccines

Publications (2)

Publication Number Publication Date
CA2713879A1 CA2713879A1 (en) 2009-09-11
CA2713879C true CA2713879C (en) 2020-01-07

Family

ID=39276265

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2713879A Active CA2713879C (en) 2008-02-01 2009-01-29 Self-assembling peptide nanoparticles useful as vaccines

Country Status (8)

Country Link
US (1) US8546337B2 (enExample)
EP (1) EP2235043A2 (enExample)
JP (1) JP6088123B2 (enExample)
CN (1) CN101932594A (enExample)
AU (1) AU2009221419B2 (enExample)
CA (1) CA2713879C (enExample)
RU (1) RU2540871C2 (enExample)
WO (1) WO2009109428A2 (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
JP2009534309A (ja) 2006-03-31 2009-09-24 マサチューセッツ インスティテュート オブ テクノロジー 治療剤の標的化送達のためのシステム
EP2019691B1 (en) 2006-05-15 2020-08-12 Massachusetts Institute of Technology Polymers for functional particles
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
EP2134830A2 (en) 2007-02-09 2009-12-23 Massachusetts Institute of Technology Oscillating cell culture bioreactor
EP2144600A4 (en) 2007-04-04 2011-03-16 Massachusetts Inst Technology POLY (AMINIC ACID) TARGET MOLECULES
EP2620157A3 (en) 2007-10-12 2013-10-16 Massachusetts Institute of Technology Vaccine nanotechnology
US20120015000A1 (en) * 2008-06-30 2012-01-19 David Lanar Malaria vaccine of self-assembling polypeptide nanoparticles
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343498B2 (en) * 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
CA2745096C (en) * 2008-12-09 2013-11-05 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
US8580274B2 (en) 2009-02-10 2013-11-12 University Of The Ryukyus Drug transporter, and adjuvant and vaccine each utilizing same
JP6282395B2 (ja) 2009-05-27 2018-02-21 セレクタ バイオサイエンシーズ インコーポレーテッドSelecta Biosciences,Inc. 異なる放出速度の構成要素を有するナノキャリア
MX343908B (es) * 2009-08-26 2016-11-28 Selecta Biosciences Inc * Composiciones que inducen la ayuda de las células t.
EP2528622A2 (en) * 2010-01-26 2012-12-05 The Regents of the University of Colorado Influenza virus epitopes templated into double-stranded coiled coils and use thereof in immunization
NO2575876T3 (enExample) * 2010-05-26 2018-05-05
EP2640190A4 (en) 2010-11-05 2016-05-11 Selecta Biosciences Inc MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS
WO2012135959A1 (en) * 2011-04-07 2012-10-11 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Protease cleavage site peptides as an hiv vaccine
US20130039954A1 (en) 2011-07-29 2013-02-14 Selecta Biosciences, Inc. Control of antibody responses to synthetic nanocarriers
CA2845886A1 (en) * 2011-08-23 2013-02-28 President And Fellows Of Harvard College Peptide nanoparticles and uses thereof
SI23902A (sl) * 2011-10-07 2013-04-30 Kemijski inštitut Samosestavljivi polipeptidni poliedri
RU2014106936A (ru) 2011-10-12 2015-11-20 Альфа-О Пептидс Аг Самосборные пептидные наночастицы в качестве вакцин против норовирусной инфекции
US9550813B2 (en) 2012-05-22 2017-01-24 The Board Of Trustees Of The Leland Stanford Junior University Disulfide stabilized foldon polypeptides
CN104582714A (zh) * 2012-05-23 2015-04-29 斯坦福大学托管董事会 流感疫苗构建体
EP2703483A1 (en) * 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
EP2922570A1 (en) 2012-11-20 2015-09-30 GlaxoSmithKline Biologicals SA Rsv f prefusion trimers
WO2014124301A1 (en) * 2013-02-07 2014-08-14 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
EP3041478A4 (en) * 2013-09-05 2017-04-26 Immune Design Corp. Vaccine compositions for drug addiction
CN104513293A (zh) * 2013-09-26 2015-04-15 深圳信立泰药业股份有限公司 一种多肽疫苗的盐及其制备方法和含有该盐的药物制品
EP3906939A1 (en) 2013-10-11 2021-11-10 The United States of America, represented by the Secretary, Department of Health and Human Services Epstein-barr virus vaccines
JP6652500B2 (ja) * 2014-01-09 2020-02-26 アルファ−オ ペプティデス アクツィエンゲゼルシャフト ワクチンプラットフォームとしてのフラジェリン含有タンパク質ナノ粒子
WO2015164798A1 (en) * 2014-04-25 2015-10-29 Tria Bioscience Corp. Synthetic hapten carrier compositions and methods
EP2974739A1 (en) 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
KR102713707B1 (ko) * 2014-12-31 2024-10-04 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 신규 다가 나노입자 기반 백신
SG11201706118XA (en) * 2015-01-29 2017-08-30 Agency Science Tech & Res Nanocapsules carrying chikungunya-associated peptides
WO2016138525A1 (en) 2015-02-27 2016-09-01 University Of Washington Polypeptide assemblies and methods for the production thereof
US9580477B2 (en) * 2015-03-16 2017-02-28 The Catholic University Of America Approach to produce HIV-1 GP140 envelope protein trimers
WO2016207782A1 (en) * 2015-06-22 2016-12-29 STRELNIKOV, Evgeny Immunogenic synthetic oligopeptides for a vaccine against hiv
CN105210995A (zh) * 2015-10-30 2016-01-06 河南科技学院 一种利用ghrelin促进新生雏鸡免疫器官发育的方法及应用
CN105409831A (zh) * 2015-10-30 2016-03-23 河南科技学院 一种利用ghrelin减少新生雏鸡脂肪细胞分化和降低脂肪沉积的方法及应用
CN105393976A (zh) * 2015-10-30 2016-03-16 河南科技学院 一种利用ghrelin促进新生雏鸡生长性能的方法及应用
US10188136B2 (en) 2016-02-16 2019-01-29 Indian Institute Of Science Education And Research Hydrophobin mimics: process for preparation thereof
FR3050448A1 (fr) * 2016-04-21 2017-10-27 Bioaster Nanoparticules a base d'encapsuline.
WO2017192434A1 (en) 2016-05-02 2017-11-09 The Scripps Research Institute Compositions and methods related to hiv-1 immunogens
JP7183149B2 (ja) 2016-09-02 2022-12-05 ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンテッド・バイ・ザ・セクレタリー・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシーズ 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用
CN110290805A (zh) * 2017-01-03 2019-09-27 埃默杰克斯疫苗控股有限公司 通用流感疫苗组合物
US20200061172A1 (en) 2017-02-23 2020-02-27 Alpha-O Peptides Ag Self-assembling protein nanoparticles encapsulating immunostimulatory nucleid acids
EA201991918A1 (ru) 2017-03-23 2020-05-15 Альфа-О Пептидс Аг Самосборные белковые наночастицы со встроенными белками с шестиспиральным пучком
WO2019023811A1 (en) 2017-08-04 2019-02-07 The Hospital For Sick Children NANOPARTICLE PLATFORM FOR ANTIBODY AND VACCINE DELIVERY
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
EP3704137A4 (en) * 2017-11-01 2021-08-11 The Scripps Research Institute NEW SCAFFOLD-TYPE ANTI-HIV-1 IMMUNOGENS
CN112135908A (zh) * 2018-01-22 2020-12-25 国立传染病研究所长代表日本国 选择性cd8阳性t细胞诱导疫苗抗原
US11225502B1 (en) * 2018-06-11 2022-01-18 Battelle Memorial Institute Controlled synthesis of hierarchically-structured hybrid materials through peptoid engineering
US11097002B2 (en) 2018-06-13 2021-08-24 The Scripps Research Institute Nanoparticle vaccines with novel structural components
US11213582B2 (en) * 2018-08-08 2022-01-04 The Regents Of The University Of California Protection against recurrent genital herpes by therapeutic immunization with herpes simplex virus type 2 ribonucleotide reductase protein subunits
RU2713723C1 (ru) * 2018-11-15 2020-02-06 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Искусственные гены, кодирующие белки-иммуногены EV.CTL и EV.Th, рекомбинантные плазмидные ДНК pEV.CTL и pEV.Th, обеспечивающие экспрессию искусственных генов, и искусственные Т-клеточные полиэпитопные белки-иммуногены EV.CTL и EV.Th, содержащие эпитопы антигенов вируса Эбола, используемые для создания вакцины против вируса Эбола
US20220088221A1 (en) 2019-01-12 2022-03-24 The Methodist Hospital Self-assembled peptide nanoparticle and use thereof
JP2022529353A (ja) 2019-04-17 2022-06-21 コンパス パスファインダー リミテッド 神経認知障害、慢性疼痛を治療し、炎症を低減させる方法
WO2020220846A1 (zh) * 2019-04-29 2020-11-05 中国人民解放军军事科学院军事医学研究院 一种可自组装为蛋白纳米颗粒的融合蛋白及其应用
CN111150842B (zh) * 2019-12-31 2023-09-05 优锐生物医药科技(深圳)有限公司 一种用于中和胃泌素的主动免疫调控微粒及其制备方法和应用
CN111150841B (zh) * 2019-12-31 2023-08-15 优锐生物医药科技(深圳)有限公司 一种主动免疫调控微粒及其制备方法和应用
CN112022066A (zh) * 2020-09-25 2020-12-04 电子科技大学 一种基于深度学习的消化道钩虫发现方法及系统
WO2022106860A1 (en) * 2020-11-20 2022-05-27 Pécsi Tudományegyetem Recombinant peptides for use in therapy
US20240316181A1 (en) * 2021-01-07 2024-09-26 Tokyo Institute Of Technology Conjugated protein monomer carrying peptide derived from pathogenic microorganism compatible with mhc molecule, aggregate of said monomers, component vaccine containing said aggregate as active ingredient, and method for acquiring information on secretion of physiologically active substance after immunization
WO2025172892A1 (en) 2024-02-16 2025-08-21 Glaxosmithkline Biologicals Sa Modified proteins and methods
WO2025242657A1 (en) 2024-05-21 2025-11-27 Shape Biopharmaceuticals Ag Lipopeptide building blocks and aggregates
CN119060144B (zh) * 2024-10-31 2025-03-18 南京澄实生物医药科技有限公司 一种预防犬瘟热病毒感染的融合蛋白和疫苗及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK519188D0 (da) * 1988-09-16 1988-09-16 Statens Seruminstitut Kemisk forbindelse
CA2037151A1 (en) * 1990-03-23 1991-09-24 F. Hoffmann-La Roche Ag Plasmodium sporozoite antigen
IL109664A0 (en) * 1993-05-18 1994-08-26 Rijksuniversiteit Peptides of human influenza virus for use in human t cell response inducing compositions
CA2337754C (en) * 1998-08-21 2011-05-24 Altaf A. Lal Recombinant multivalent malarial vaccine against plasmodium falciparum
WO2000032227A2 (en) * 1998-11-30 2000-06-08 Cytos Biotechnology Ag Ordered molecular presentation of antigens, method of preparation and use
US6756039B1 (en) * 1999-05-10 2004-06-29 The Regents Of The University Of California Self assembling proteins
DE60014372T2 (de) * 1999-06-25 2006-02-02 The Governors Of The University Of Alberta, Edmonton Polypeptid-enthaltende zusammensetzungen, hergestellt durch verwendung von matrizen in gestalt eines coiled-coil und deren gebrauch
JP2003532740A (ja) * 2000-05-05 2003-11-05 アフトン コーポレーション キメラペプチド免疫原
WO2002100325A2 (en) * 2000-10-13 2002-12-19 Ligocyte Pharmaceuticals, Inc. Polyvalent nanoparticles
AU2002349204A1 (en) * 2001-11-26 2003-06-10 University Health Network Self-assembling p53 peptides as gene delivery vehicles
DE602004008582T2 (de) * 2003-02-17 2008-05-21 Peter Burkhard Peptidische nanoteilchen als arzneimittelabgabe- und antigen-display-systeme
EP1773303A2 (en) 2004-05-25 2007-04-18 Chimeracore, Inc. Self-assembling nanoparticle drug delivery system

Also Published As

Publication number Publication date
CN101932594A (zh) 2010-12-29
AU2009221419A1 (en) 2009-09-11
EP2235043A2 (en) 2010-10-06
WO2009109428A2 (en) 2009-09-11
JP2011511773A (ja) 2011-04-14
US8546337B2 (en) 2013-10-01
US20110020378A1 (en) 2011-01-27
RU2540871C2 (ru) 2015-02-10
WO2009109428A3 (en) 2010-04-01
AU2009221419B2 (en) 2013-09-26
CA2713879A1 (en) 2009-09-11
RU2010135965A (ru) 2012-03-10
JP6088123B2 (ja) 2017-03-01

Similar Documents

Publication Publication Date Title
CA2713879C (en) Self-assembling peptide nanoparticles useful as vaccines
Hamley Peptides for vaccine development
US11324836B2 (en) Modified virus-like particles of CMV
AU2012204955B2 (en) Monomeric and multimeric immunogenic peptides
CN101113178A (zh) 包含辅助t细胞和细胞毒性t淋巴细胞(ctl)表位的新免疫原性脂肽
US10501499B2 (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
US20140242104A1 (en) Self-assembling peptide nanoparticles as vaccines against infection with norovirus
Haro et al. Design of synthetic peptidic constructs for the vaccine development against viral infections
RU2358981C2 (ru) Универсальная вакцина против вируса гриппа птиц
HU196131B (en) Process for preparing polypeptide vaccine
US11535651B2 (en) Hepatitis B nanoparticle-based vaccine for influenza virus
HK1152533A (en) Self-assembling peptide nanoparticles useful as vaccines
CN115916237A (zh) 抗病毒病原体的疫苗
CN107624117A (zh) 基于乙型肝炎核心抗原的疫苗
JP2014508144A (ja) 免疫応答を刺激するためのプラットフォーム技術を利用するコンジュゲート

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131114